Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Clinical trial NCT03742349 · TERMINATED
Trial details
- NCT number
- NCT03742349
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-31
- Primary completion
- 2023-02-06
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.